Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 5/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757193 | 0.94 | MEN1 (0.43) | MEN1KMT2AL3MBTL1ATMTPMT | |
| SCHEMBL2757185 | 0.83 | PDE3B (0.41) | MEN1KMT2AL3MBTL1ATMMAPT | |
| SCHEMBL3474066 | 0.80 | KMT2A (0.52) | MEN1KMT2AATMMAPTHPGD | |
| SCHEMBL3472763 | 0.76 | TAAR1 (0.58) | MEN1KMT2AL3MBTL1MAPTHPGD | |
| SCHEMBL3471960 | 0.76 | BCL2 (0.55) | MEN1KMT2AMAPTHPGDPOLB | |
| SCHEMBL9774171 | 0.75 | TPMT (0.55) | MEN1KMT2AL3MBTL1TPMTMAPT | |
| SCHEMBL5588217 | 0.75 | CYP3A4 (0.56) | MEN1KMT2AL3MBTL1TPMTMAPT | |
| SCHEMBL3473620 | 0.75 | PGR (0.48) | MEN1KMT2AMAPTHPGDPOLB | |
| SCHEMBL2622282 | 0.74 | PDE3B (0.43) | MEN1KMT2AMAPTCYP3A4KDM4E | |
| SCHEMBL7179558 | 0.73 | LDHA (0.56) | MEN1KMT2AL3MBTL1ATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418942-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8937193-B2 | Apogossypolone derivatives as anticancer agents | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-20 | — | — | US | disclosed |
| US-8487131-B2 | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-07-16 | — | — | US | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-01-05 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | CYP17A1, HSD17B7, CYP27A1 | MEN1 809/4885KMT2A 4581/4885L3MBTL1 4816/4885 |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | MEN1 4843/4885KMT2A 4765/4885L3MBTL1 2258/4885 |
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | BCL3, BCL9, BCL2 | MEN1 4183/4885KMT2A 3920/4885L3MBTL1 3191/4885 |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | HAX1, PRDX1, APOL1 | MEN1 4790/4885KMT2A 4720/4885L3MBTL1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.